

ZELTIA NEWS:

GENOMICA DEVELOPS NEW DIAGNOSTIC KITS FOR SOMATIC MUTATIONS THAT ARE DETERMINANT IN ANTI-TUMOUR THERAPIES

GENOMICA has laid the groundwork for an R&D and innovation project related to its CLART® CMA (Cancer Mutation Analysis) diagnostic kit and has established an agreement with the Molecular Pathology Department of Hvidovre University Hospital in Copenhagen.

Madrid, 20 March 2013: GENOMICA S.A.U., a company in Grupo Zeltia (ZEL:MC), has laid the foundations for a research, development and innovation project linked to its CLART® CMA (Cancer Mutation Analysis) diagnostic kit by means of a cooperation agreement with agreement with the Molecular Pathology Department of Hvidovre University Hospital in Copenhagen. The first contacts were made in 2011 with the goal of developing a new diagnostic tool to allow physicians to choose the appropriate treatment for cancer patients. The first product of this cooperation, CLART® CMA KRAS·BRAF·PI3K, was launched in April 2012 and is now used in many pathology labs worldwide, as well as being cited as the benchmark diagnostic method in the new Danish national guidelines for BRAF diagnosis, as published by the Danish Pathology Society (DSP, Danske Samfund Patologi).

The new guidelines issued by ASCO (American Society of Clinical Oncology) and ESMO (European Society of Medical Oncology) for the use of drugs in colorectal cancer require a test of the mutational status of the KRAS oncogene prior to treatment of any patient with metastatic colorectal cancer. GENOMICA and the Molecular Pathology Department of the Hvidovre Hospital considered it would be valuable to work together in developing a diagnostic option for these patients that would provide faster and more robust sample analysis in a way that could be incorporated into the standard lab routine.



Eighteen months later, based on sterling work by both parties, the CLART® CMA KRAS·BRAF·PI3K, their first kit in this new diagnostics line, came into being. Work is currently being performed to develop new kits in the CLART® CMA line that are focused on the EGFR receptor; they are expected to be available in 2014.

Based on the success of their collaboration, last week GENOMICA A.B. (the Swedish subsidiary of GENOMICA S.A.U.) visited the Hvidovre Hospital in Copenhagen to discuss future initiatives. Present at the meeting were Dr. Rosario Cospedal (general manager of GENOMICA S.A.U.), Juan Bataller (general manager of GENOMICA AB), Dr. Torben Mogensen (Deputy Director of the Hospital), Dr. Carsten Rygaard (head of the Pathology Department) and Jesper Bonde (head of the molecular pathology lab).

About Zeltia

Zeltia S.A. is a world-leading biopharmaceutical company specialized in the development of marine-based drugs for use in oncology and central nervous system illnesses. Grupo Zeltia consists mainly of the following companies: PharmaMar, the world-leading biotechnology company in advancing cancer care through the discovery and development of innovative marine-derived medicines; GENOMICA, Spain's leading molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi); and a chemical division comprising Zelnova and Xylazel, two highly profitable companies that are leaders in their respective market segments.

About GENOMICA

GENOMICA S.A.U. is Spain's leading molecular diagnostics company. Founded in 1990, the company is based in the Madrid region. It is wholly owned by Zeltia. The company's mission is to apply quality and automation to improve the current approach to molecular diagnostics in the life sciences. The company's main goal is to lead the Spanish market in genomic applications and expand internationally in the area of molecular diagnostics and personalized medicine by designing, developing and selling new diagnostic applications based on the CLART® (CLINICAL ARRAY TECHNOLOGY) platform. GENOMICA has developed a diagnostic test for human papilloma virus (associated with cervical cancer), a system for diagnosing respiratory viruses, and a method for detecting human herpes virus; it also markets a test for detecting genetic markers associated with response to therapy. GENOMICA is a leading supplier of genetic identification services in legal and forensic medicine and in technology transfer (turnkey laboratories). <http://www.genomica.es/>

For more information, contact Zeltia at +34 91 444 4500